JP2024516575A5 - - Google Patents
Info
- Publication number
- JP2024516575A5 JP2024516575A5 JP2023562827A JP2023562827A JP2024516575A5 JP 2024516575 A5 JP2024516575 A5 JP 2024516575A5 JP 2023562827 A JP2023562827 A JP 2023562827A JP 2023562827 A JP2023562827 A JP 2023562827A JP 2024516575 A5 JP2024516575 A5 JP 2024516575A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- tlr7
- immunomodulatory composition
- motif
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176128P | 2021-04-16 | 2021-04-16 | |
| US63/176,128 | 2021-04-16 | ||
| PCT/US2022/025128 WO2022221736A2 (en) | 2021-04-16 | 2022-04-15 | Optimized tlr7 ligands and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516575A JP2024516575A (ja) | 2024-04-16 |
| JP2024516575A5 true JP2024516575A5 (cg-RX-API-DMAC7.html) | 2025-04-18 |
Family
ID=81940670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562827A Pending JP2024516575A (ja) | 2021-04-16 | 2022-04-15 | 最適化されたtlr7リガンド及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240042019A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4323525A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516575A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117203340A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022221736A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4601656A1 (en) * | 2022-10-12 | 2025-08-20 | Pharmorage Pty Limited | Modified oligonucleotides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JP2007526253A (ja) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激性ウイルスrnaオリゴヌクレオチド |
| JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| WO2006063252A2 (en) * | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| EP1924284A1 (en) * | 2005-09-14 | 2008-05-28 | Hartmann, Gunther | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides |
| KR101343489B1 (ko) * | 2007-07-09 | 2013-12-20 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역 조절성 rna(simra)화합물 |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| EP2396409A2 (en) * | 2009-02-10 | 2011-12-21 | Idera Pharmaceuticals, Inc. | Synthetic rna-based agonists of tlr7 |
| EP3263707A1 (en) | 2009-03-17 | 2018-01-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Tlr8 ligand and uses thereof |
| US9187746B2 (en) * | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| CN116549671A (zh) | 2016-11-10 | 2023-08-08 | 川斯勒佰尔公司 | 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂 |
| WO2020214946A1 (en) | 2019-04-18 | 2020-10-22 | Translate Bio, Inc. | Cystine cationic lipids |
| WO2020219941A1 (en) | 2019-04-26 | 2020-10-29 | Genevant Sciences Gmbh | Lipid nanoparticles |
-
2022
- 2022-04-15 CN CN202280028901.4A patent/CN117203340A/zh active Pending
- 2022-04-15 WO PCT/US2022/025128 patent/WO2022221736A2/en not_active Ceased
- 2022-04-15 JP JP2023562827A patent/JP2024516575A/ja active Pending
- 2022-04-15 EP EP22726552.7A patent/EP4323525A2/en active Pending
-
2023
- 2023-10-12 US US18/485,987 patent/US20240042019A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7115579B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
| KR102434357B1 (ko) | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 | |
| JP2025106391A (ja) | 免疫賦活特性が減少したrna組み合わせおよび組成物 | |
| US7176296B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
| JP2021526804A5 (cg-RX-API-DMAC7.html) | ||
| KR101835401B1 (ko) | 키랄 핵산 어쥬번트 | |
| CN101460178B (zh) | 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物 | |
| JP2023179428A (ja) | メッセンジャーリボ核酸(mRNA)をコードする安定化された核酸 | |
| US7709449B2 (en) | Nucleic acid-based compounds and methods of use thereof | |
| US7105495B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
| JP2019527694A (ja) | B型肝炎ウイルス感染のためのRNAi薬 | |
| JPH08502040A (ja) | ハイブリッド オリゴヌクレオチド ホスホロチオエート | |
| WO1997029757A1 (en) | Rnase l activators and antisense oligonucleotides effective to treat rsv infections | |
| CN114206463A (zh) | 脂质化合物和脂质纳米颗粒组合物 | |
| JP2008523094A5 (cg-RX-API-DMAC7.html) | ||
| CN115176009A (zh) | 用于靶向pd-l1的方法和组合物 | |
| AU2010213795A1 (en) | Synthetic RNA-based agonists of TLR7 | |
| JP2014532400A (ja) | 免疫賦活用の二本鎖rna | |
| EP2943251B1 (en) | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response | |
| US20240327847A1 (en) | Compositions and methods for rna affinity | |
| JP2024539093A (ja) | 2’-デオキシ-2’-f-2’-c-メチルヌクレオチドを有するオリゴヌクレオチド | |
| TW202313068A (zh) | 用於抑制黏蛋白5AC(MUC5AC)表現之RNAi藥劑、其組合物及使用方法 | |
| JP2024541701A5 (cg-RX-API-DMAC7.html) | ||
| WO2003062258A1 (en) | Rnase l activator-antisense complexes | |
| KR100257972B1 (ko) | 높은 키랄 순도의 포스포로티오에이트 결합기를 가지는 올리고뉴클레오티드 |